Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2025 · 10-Q
Revenue$209.36M$209.36M+31.4% vs Q3 2024 Net Income$31.51M$31.51M+237.5% vs Q3 2024 EPS Diluted$0.84$0.84+211.1% vs Q3 2024 Gross Profit$129,171,000+33.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$78,438,000N/M Free Cash Flowderived$78,250,000N/M Margins · derivedGross margin61.7%+0.9 pt vs Q3 2024
Operating margin29.7%+7.8 pt vs Q3 2024
Net margin15.0%+9.2 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end